1 |
Lusis, E. A., Watson, M. A., Chicoine, M. R., Lyman, M., Roerig, P., Reifenberger, G., Gutmann, D. H. and Perry, A. (2005). Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res. 65, 7121- 7126.
DOI
ScienceOn
|
2 |
Qu, X., Zhai, Y., Wei, H., Zhang, C., Xing, G., Yu, Y. and He, F. (2002). Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family. Mol. Cell. Biochem. 229, 35-44.
DOI
ScienceOn
|
3 |
Wang, Y. A., Johnson, S. K., Brown, B. L., McCarragher, L. M., Al-Sakkaf, K., Royds, J. A. and Dobson, P. R. (2008). Enhanced anti-cancer effect of a phosphatidylinositol-3 kinase inhibitor and doxorubicin on human breast epithelial cell lines with different p53 and oestrogen receptor status. Int. J. Cancer 123, 1536-1544.
DOI
ScienceOn
|
4 |
Garcia, R., Bowman, T. L., Niu, G., Yu, H., Minton, S., Muro- Cacho, C. A., Cox, C. E., Falcone, R., Fairclough, R., Parsons, S., Laudano, A., Gazit, A., Levitzki, A., Kraker, A. and Jove, R. (2001). Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20, 2499-2513.
DOI
|
5 |
Ishii, Y., Waxman, S. and Germain, D. (2008). Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3. Cancer Res. 68, 852-860.
DOI
ScienceOn
|
6 |
Lachat, P., Shaw, P., Gebhard, S., van Belzen, N., Chaubert, P. and Bosman, F. T. (2002). Expression of NDRG1, a differentiation-related gene, in human tissues. Histochem. Cell Biol. 118, 399-408.
DOI
|
7 |
Deng, Y., Yao, L., Chau, L., Ng, S. S., Peng, Y., Liu, X., Au, W. S., Wang, J., Li, F., Ji, S., Han, H., Nie, X., Li, Q., Kung, H. F., Leung, S. Y. and Lin, M. C. (2003). N-Myc downstreamregulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int. J. Cancer 106, 342-347.
DOI
ScienceOn
|
8 |
Zhou, R. H., Kokame, K., Tsukamoto, Y., Yutani, C., Kato, H. and Miyata, T. (2001). Characterization of the human NDRG gene family: a newly identified member, NDRG4, is specifically expressed in brain and heart. Genomics 73, 86-97.
DOI
ScienceOn
|
9 |
Johnstone, R. W., Ruefli, A. A. and Lowe, S. W. (2002). Apoptosis: a link between cancer genetics and chemotherapy. Cell 108, 153-164.
DOI
ScienceOn
|
10 |
Kim, Y. J., Yoon, S. Y., Kim, J. T., Choi, S. C., Lim, J. S., Kim, J. H., Song, E. Y., Lee, H. G., Choi, I. and Kim, J. W. (2008). NDRG2 suppresses cell proliferation through down-regulation of AP-1 activity in human colon carcinoma cells. Int. J. Cancer 124, 7-15.
DOI
ScienceOn
|
11 |
Lui, N., Wang, L., Li, X., Yang, Q., Liu, X., Zhang, J., Zhang, J., Wu, Y., Ji, S., Zhang, Y., Yang, A., Han, H. and Yao, L. (2008). N-Myc downstream-regulated gene 2 is involved in p53-mediated apoptosis. Nucl. Acid Res. 36, 5335-5349.
DOI
ScienceOn
|
12 |
Okuda, T. and Kondoh, H. (1999). Identification of new genes ndr2 and ndr3 which are related to Ndr1/RTP/Drg1 but show distinct tissue specificity and response to N-myc. Biochem. Biophys. Res. Commun. 266, 208-215.
DOI
ScienceOn
|
13 |
Park, Y., Shon, S. K., Kim, A., Kim, K. I., Yang, Y., Cho, D. H., Lee, M. S. and Lim, J. S. (2007). SOCS1 induced by NDRG2 expression negatively regulates STAT3 activation in breast cancer cells. Biochem. Biophys. Res. Commun. 363, 361-367.
DOI
ScienceOn
|
14 |
Swift, L. P., Cutts, S. M., Nudelman, A., Levovich, I., Rephaeli, A. and Phillips, D. R. (2008). The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity. Cancer Chemother. Pharmacol. 61, 739-749.
DOI
|
15 |
Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J. M., Yang-Yen, H. F., Karras, J., Jove, R. and Loughran, T. P. Jr. (2001). Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest. 107, 351- 362.
DOI
ScienceOn
|
16 |
Choi, S. C., Yoon, S. R., Park, Y. P., Song, E. Y., Kim, J. W., Kim, W. H., Yang, Y., Lim, J. S. and Lee, H. G. (2007). Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death. Exp. Mol. Med. 39, 705-714.
DOI
ScienceOn
|
17 |
Costantino, L. and Barlocco, D. (2008). STAT 3 as a target for cancer drug discovery. Curr. Med. Chem. 15, 834-843.
DOI
ScienceOn
|
18 |
Decker, P. and Muller, S. (2002). Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress. Curr. Pharm. Biotech. 3, 275-283.
DOI
ScienceOn
|
19 |
Fornari, F. A., Randolph, J. K., Yalowich, J. C., Ritke, M. K. and Gewirtz, D. A. (1994). Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol. Pharmacol. 45, 649-656.
|
20 |
Gariboldi, M. B., Ravizza, R., Molteni, R., Osella, D., Gabano, E. and Monti, E. (2007). Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Lett. 258, 181-188.
DOI
ScienceOn
|
21 |
Ghobrial, I. M., Witzig, T. E. and Adjei, A. A. (2005). Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 55, 178-194.
DOI
ScienceOn
|
22 |
Aggarwal, B. B., Sethi, G., Ahn, K. S., Sandur, S. K., Pandey, M. K., Kunnumakkara, A. B., Sung, B. and Ichikawa, H. (2006). Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann. N. Y. Acad. Sci. 1091, 151-169.
DOI
ScienceOn
|
23 |
Hu, X. L., Liu, X. P., Lin, S. X., Deng, Y. C., Liu, N., Li, X. and Yao, L. B. (2004). NDRG2 expression and mutation in human liver and pancreatic cancers. World J. Gastroenterol. 10, 3518-3521.
DOI
|